Review



pp3 #529574  (Millipore)


Bioz Verified Symbol Millipore is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Millipore pp3 #529574
    Pp3 #529574, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp3/pp3++529574/pm40537792-343-3-8
    Average 90 stars, based on 1 article reviews
    pp3 #529574 - by Bioz Stars, 2026-11
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: The CXCL12/CXCR4 Axis Promotes Ligand-Independent Activation of the Androgen Receptor
    Article Snippet: The effects of the PI3 kinase inhibitor, wortmannin (Sigma, #W1628), the MAPK MEK/ERK inhibitor, U0126 (Cell Signaling, #9903), the PKC inhibitor, bisindolylaeimide I, BISI, (Calbiochem, #203290), the Src family kinase inhibitor, PP1 (Invitrogen) and its inactive analog, PP3 (Calbiochem, #529574) on CXCL12- stimulated PSA secretion was examined by pre-treating the overnight sera deprived cells with 1uM wortmannin, 10uM U0126, 10uM BISI, 10uM PP1, 10uM PP3 or vehicle (0.1% DMSO), for 1hr, followed by treatment with 1nM R1881 or 50pM CXCL12 for 48hrs.

    Article Title: 12/15-Lipoxygenase-dependent ROS production is required for diet-induced endothelial barrier dysfunction
    Article Snippet: PP3 (529574) was bought from Calbiochem (Billerica, MA).

    Article Title: The Src family kinase inhibitor drug Dasatinib and glucocorticoids display synergistic activity against tongue squamous cell carcinoma and reduce MET kinase activity.
    Article Snippet: PP2 (#529573) and PP3 (#529574) were purchased from Calbiochem, Dasatinib (#HY-10181) from Hycultec, and Crizotinib (#S1068) from Selleckchem.

    Article Title: Novel role of cortactin in G protein-coupled receptor agonist-induced nuclear export and degradation of p21Cip1
    Article Snippet: PP1 (567809), PP2 (529573) and PP3 (529574) were bought from Calbiochem (Billerica, MA).

    Article Title: Crystal-induced neutrophil activation: XI. Implication and novel roles of classical protein kinase C.
    Article Snippet: Gö6976 (catalog no. 365250), PP2 (catalog no. 529573, 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo(3,4D-pyrimidine)), and PP3 (529574, 4-amino-7-phenylpyrazol(3,4-D-pyrimidine)) were purchased from Calbiochem.

    Article Title: 12/15-Lipoxygenase-dependent ROS production is required for diet-induced endothelial barrier dysfunction
    Article Snippet: PP3 (529574) was bought from Calbiochem (Billerica, MA).

    Incubation:

    Article Title: Odin (ANKS1A) is a Src family kinase target in colorectal cancer cells
    Article Snippet: Anti-pY419Src (polyclonal rabbit, 2101; Cell Signaling Technology) reacts with all members of the SFK family expressed in CRC cells due to high conservation of the target epitope (for further details see [5]). .. Treatment of SW620 cells with kinase inhibitors SW620 cells were incubated with 30 μM SFK inhibitor PP2 (529573; Calbiochem) dissolved in DMSO, or the structural analogue PP3, which lacks SFK inhibitory activity (529574; Calbiochem), or with the compound solvent (D2650; Sigma-Alrich) alone for 24 h. Cells were then harvested by lysing in RIPA buffer [5] and protein concentrations determined by Bradford assay. .. Cell extracts were also probed for actin (mAb, A3853; Sigma-Aldrich) as a loading control.

    Activity Assay:

    Article Title: Odin (ANKS1A) is a Src family kinase target in colorectal cancer cells
    Article Snippet: Anti-pY419Src (polyclonal rabbit, 2101; Cell Signaling Technology) reacts with all members of the SFK family expressed in CRC cells due to high conservation of the target epitope (for further details see [5]). .. Treatment of SW620 cells with kinase inhibitors SW620 cells were incubated with 30 μM SFK inhibitor PP2 (529573; Calbiochem) dissolved in DMSO, or the structural analogue PP3, which lacks SFK inhibitory activity (529574; Calbiochem), or with the compound solvent (D2650; Sigma-Alrich) alone for 24 h. Cells were then harvested by lysing in RIPA buffer [5] and protein concentrations determined by Bradford assay. .. Cell extracts were also probed for actin (mAb, A3853; Sigma-Aldrich) as a loading control.

    Solvent:

    Article Title: Odin (ANKS1A) is a Src family kinase target in colorectal cancer cells
    Article Snippet: Anti-pY419Src (polyclonal rabbit, 2101; Cell Signaling Technology) reacts with all members of the SFK family expressed in CRC cells due to high conservation of the target epitope (for further details see [5]). .. Treatment of SW620 cells with kinase inhibitors SW620 cells were incubated with 30 μM SFK inhibitor PP2 (529573; Calbiochem) dissolved in DMSO, or the structural analogue PP3, which lacks SFK inhibitory activity (529574; Calbiochem), or with the compound solvent (D2650; Sigma-Alrich) alone for 24 h. Cells were then harvested by lysing in RIPA buffer [5] and protein concentrations determined by Bradford assay. .. Cell extracts were also probed for actin (mAb, A3853; Sigma-Aldrich) as a loading control.

    Bradford Assay:

    Article Title: Odin (ANKS1A) is a Src family kinase target in colorectal cancer cells
    Article Snippet: Anti-pY419Src (polyclonal rabbit, 2101; Cell Signaling Technology) reacts with all members of the SFK family expressed in CRC cells due to high conservation of the target epitope (for further details see [5]). .. Treatment of SW620 cells with kinase inhibitors SW620 cells were incubated with 30 μM SFK inhibitor PP2 (529573; Calbiochem) dissolved in DMSO, or the structural analogue PP3, which lacks SFK inhibitory activity (529574; Calbiochem), or with the compound solvent (D2650; Sigma-Alrich) alone for 24 h. Cells were then harvested by lysing in RIPA buffer [5] and protein concentrations determined by Bradford assay. .. Cell extracts were also probed for actin (mAb, A3853; Sigma-Aldrich) as a loading control.



    Similar Products

    updated guidelines for use of pvs1 and pp3 criteria  (ClinGen Resource)
    90
    ClinGen Resource updated guidelines for use of pvs1 and pp3 criteria
    Updated Guidelines For Use Of Pvs1 And Pp3 Criteria, supplied by ClinGen Resource, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp3/pvs1/pm40640912-60-11-3
    Average 90 stars, based on 1 article reviews
    updated guidelines for use of pvs1 and pp3 criteria - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    pp3  (Tocris)
    93
    Tocris pp3
    Concentration-response relationships of ( A ) DAMGO as a recruiter of β-arrestin2 to human μ receptors in PathHunter CHO cells and ( B ) DAMGO as an inhibitor of forskolin (30 μM) stimulated cAMP accumulation in the same cell line transiently expressing the pGloSensor-22F protein following 16 h exposure to 1 μM PP2, <t>PP3,</t> eCF506 or an equal volume of DMSO. (A) Data are expressed as a percentage of maximum luminescence (% Max RLU) produced by DAMGO in DMSO exposed cells present in duplicate on each 96-well plate. The insert demonstrates c-Src phosphorylation at Y416 (upper panel) and total c-Src (lower panel) expression assessed using western blot in each cell lysate following overnight exposure and confirms inhibition of c-Src phosphorylation. (B) Data are expressed as a percentage of luminescence in each well measured prior to the addition of agonist (% control). Data from individual replicates were plotted and fitted with logistics functions to derive efficacy (E MAX ) and potency (EC 50 /IC 50 ) parameters, presented in . Data are the mean ± SEM of 5 replicates (A) and 8 replicates (B).
    Pp3, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp3/PP+3/bio_rxiv__2025__07__01__662507-171-34-42
    Average 93 stars, based on 1 article reviews
    pp3 - by Bioz Stars, 2026-11
    93/100 stars
    		  Buy from Supplier
    pp3/bp4  (ClinGen Resource)
    90
    ClinGen Resource pp3/bp4
    Concentration-response relationships of ( A ) DAMGO as a recruiter of β-arrestin2 to human μ receptors in PathHunter CHO cells and ( B ) DAMGO as an inhibitor of forskolin (30 μM) stimulated cAMP accumulation in the same cell line transiently expressing the pGloSensor-22F protein following 16 h exposure to 1 μM PP2, <t>PP3,</t> eCF506 or an equal volume of DMSO. (A) Data are expressed as a percentage of maximum luminescence (% Max RLU) produced by DAMGO in DMSO exposed cells present in duplicate on each 96-well plate. The insert demonstrates c-Src phosphorylation at Y416 (upper panel) and total c-Src (lower panel) expression assessed using western blot in each cell lysate following overnight exposure and confirms inhibition of c-Src phosphorylation. (B) Data are expressed as a percentage of luminescence in each well measured prior to the addition of agonist (% control). Data from individual replicates were plotted and fitted with logistics functions to derive efficacy (E MAX ) and potency (EC 50 /IC 50 ) parameters, presented in . Data are the mean ± SEM of 5 replicates (A) and 8 replicates (B).
    Pp3/Bp4, supplied by ClinGen Resource, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp3/clingen+proposed+pp3+bp4+score+thresholds/pm40616174-73-10-1
    Average 90 stars, based on 1 article reviews
    pp3/bp4 - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    pp3 #529574  (Millipore)
    90
    Millipore pp3 #529574
    Concentration-response relationships of ( A ) DAMGO as a recruiter of β-arrestin2 to human μ receptors in PathHunter CHO cells and ( B ) DAMGO as an inhibitor of forskolin (30 μM) stimulated cAMP accumulation in the same cell line transiently expressing the pGloSensor-22F protein following 16 h exposure to 1 μM PP2, <t>PP3,</t> eCF506 or an equal volume of DMSO. (A) Data are expressed as a percentage of maximum luminescence (% Max RLU) produced by DAMGO in DMSO exposed cells present in duplicate on each 96-well plate. The insert demonstrates c-Src phosphorylation at Y416 (upper panel) and total c-Src (lower panel) expression assessed using western blot in each cell lysate following overnight exposure and confirms inhibition of c-Src phosphorylation. (B) Data are expressed as a percentage of luminescence in each well measured prior to the addition of agonist (% control). Data from individual replicates were plotted and fitted with logistics functions to derive efficacy (E MAX ) and potency (EC 50 /IC 50 ) parameters, presented in . Data are the mean ± SEM of 5 replicates (A) and 8 replicates (B).
    Pp3 #529574, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp3/pp3++529574/pm40537792-343-3-8
    Average 90 stars, based on 1 article reviews
    pp3 #529574 - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    inactive analogue pp3  (Cosmo Bio USA)
    90
    Cosmo Bio USA inactive analogue pp3
    Concentration-response relationships of ( A ) DAMGO as a recruiter of β-arrestin2 to human μ receptors in PathHunter CHO cells and ( B ) DAMGO as an inhibitor of forskolin (30 μM) stimulated cAMP accumulation in the same cell line transiently expressing the pGloSensor-22F protein following 16 h exposure to 1 μM PP2, <t>PP3,</t> eCF506 or an equal volume of DMSO. (A) Data are expressed as a percentage of maximum luminescence (% Max RLU) produced by DAMGO in DMSO exposed cells present in duplicate on each 96-well plate. The insert demonstrates c-Src phosphorylation at Y416 (upper panel) and total c-Src (lower panel) expression assessed using western blot in each cell lysate following overnight exposure and confirms inhibition of c-Src phosphorylation. (B) Data are expressed as a percentage of luminescence in each well measured prior to the addition of agonist (% control). Data from individual replicates were plotted and fitted with logistics functions to derive efficacy (E MAX ) and potency (EC 50 /IC 50 ) parameters, presented in . Data are the mean ± SEM of 5 replicates (A) and 8 replicates (B).
    Inactive Analogue Pp3, supplied by Cosmo Bio USA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp3/inactive+analogue+pp3/pm40533081-127-10-20
    Average 90 stars, based on 1 article reviews
    inactive analogue pp3 - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    pathogenicity assertions d, pm2_p, pm3_vs, pp1_s, pp3, pp4 【pathogenic】 (this study)  (ClinGen Resource)
    90
    ClinGen Resource pathogenicity assertions d, pm2_p, pm3_vs, pp1_s, pp3, pp4 【pathogenic】 (this study)
    Concentration-response relationships of ( A ) DAMGO as a recruiter of β-arrestin2 to human μ receptors in PathHunter CHO cells and ( B ) DAMGO as an inhibitor of forskolin (30 μM) stimulated cAMP accumulation in the same cell line transiently expressing the pGloSensor-22F protein following 16 h exposure to 1 μM PP2, <t>PP3,</t> eCF506 or an equal volume of DMSO. (A) Data are expressed as a percentage of maximum luminescence (% Max RLU) produced by DAMGO in DMSO exposed cells present in duplicate on each 96-well plate. The insert demonstrates c-Src phosphorylation at Y416 (upper panel) and total c-Src (lower panel) expression assessed using western blot in each cell lysate following overnight exposure and confirms inhibition of c-Src phosphorylation. (B) Data are expressed as a percentage of luminescence in each well measured prior to the addition of agonist (% control). Data from individual replicates were plotted and fitted with logistics functions to derive efficacy (E MAX ) and potency (EC 50 /IC 50 ) parameters, presented in . Data are the mean ± SEM of 5 replicates (A) and 8 replicates (B).
    Pathogenicity Assertions D, Pm2 P, Pm3 Vs, Pp1 S, Pp3, Pp4 【Pathogenic】 (This Study), supplied by ClinGen Resource, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp3/pathogenicity+assertions+d++pm2+p++pm3+vs++pp1+s++pp3++pp4+%E3%80%90pathogenic%E3%80%91++this+study+/pmc12063237-103-7-19
    Average 90 stars, based on 1 article reviews
    pathogenicity assertions d, pm2_p, pm3_vs, pp1_s, pp3, pp4 【pathogenic】 (this study) - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    pp3 5334-30-5  (Tokyo Chemical Industry)
    90
    Tokyo Chemical Industry pp3 5334-30-5
    Concentration-response relationships of ( A ) DAMGO as a recruiter of β-arrestin2 to human μ receptors in PathHunter CHO cells and ( B ) DAMGO as an inhibitor of forskolin (30 μM) stimulated cAMP accumulation in the same cell line transiently expressing the pGloSensor-22F protein following 16 h exposure to 1 μM PP2, <t>PP3,</t> eCF506 or an equal volume of DMSO. (A) Data are expressed as a percentage of maximum luminescence (% Max RLU) produced by DAMGO in DMSO exposed cells present in duplicate on each 96-well plate. The insert demonstrates c-Src phosphorylation at Y416 (upper panel) and total c-Src (lower panel) expression assessed using western blot in each cell lysate following overnight exposure and confirms inhibition of c-Src phosphorylation. (B) Data are expressed as a percentage of luminescence in each well measured prior to the addition of agonist (% control). Data from individual replicates were plotted and fitted with logistics functions to derive efficacy (E MAX ) and potency (EC 50 /IC 50 ) parameters, presented in . Data are the mean ± SEM of 5 replicates (A) and 8 replicates (B).
    Pp3 5334 30 5, supplied by Tokyo Chemical Industry, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp3/pp3+5334+30+5/pmc11903687-425-27-30
    Average 90 stars, based on 1 article reviews
    pp3 5334-30-5 - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    clingen-proposed pp3/bp4 score thresholds  (ClinGen Resource)
    90
    ClinGen Resource clingen-proposed pp3/bp4 score thresholds
    (A) The presence of either gain-of-function or loss-of-function mutations in cancer driver genes can lead to cancer (left) or rare Mendelian disorders (right) in different contexts. Most cancers result from somatic mutations that accumulate in a tissue-specific manner, whereas germline mutations are present in all cells of the body and cause a type of rare Mendelian disorder (e.g., neurodevelopmental disorder). (B) The HRAS Q61K mutation is an example of a known cancer mutation that drives different types of cancers that also causes Costello syndrome, a developmental disorder, when observed as a germline variant. (C) Workflow for extracting cancer mutations from Cancer Hotspots. Recurrent cancer mutations were filtered to 2,447 missense mutations. See main text for details. REVEL scores thresholds correspond to supporting evidence for pathogenicity <t>(PP3)</t> and for benign-ness <t>(BP4).</t> Created with Lucidchart. Created with BioRender.
    Clingen Proposed Pp3/Bp4 Score Thresholds, supplied by ClinGen Resource, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp3/clingen+proposed+pp3+bp4+score+thresholds/pmc11737861-61-11-10
    Average 90 stars, based on 1 article reviews
    clingen-proposed pp3/bp4 score thresholds - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Concentration-response relationships of ( A ) DAMGO as a recruiter of β-arrestin2 to human μ receptors in PathHunter CHO cells and ( B ) DAMGO as an inhibitor of forskolin (30 μM) stimulated cAMP accumulation in the same cell line transiently expressing the pGloSensor-22F protein following 16 h exposure to 1 μM PP2, PP3, eCF506 or an equal volume of DMSO. (A) Data are expressed as a percentage of maximum luminescence (% Max RLU) produced by DAMGO in DMSO exposed cells present in duplicate on each 96-well plate. The insert demonstrates c-Src phosphorylation at Y416 (upper panel) and total c-Src (lower panel) expression assessed using western blot in each cell lysate following overnight exposure and confirms inhibition of c-Src phosphorylation. (B) Data are expressed as a percentage of luminescence in each well measured prior to the addition of agonist (% control). Data from individual replicates were plotted and fitted with logistics functions to derive efficacy (E MAX ) and potency (EC 50 /IC 50 ) parameters, presented in . Data are the mean ± SEM of 5 replicates (A) and 8 replicates (B).

    Journal: bioRxiv

    Article Title: The c-Src inhibitor eCF506 diminishes opioid tolerance creating bias against β-arrestin2 recruitment

    doi: 10.1101/2025.07.01.662507

    Figure Lengend Snippet: Concentration-response relationships of ( A ) DAMGO as a recruiter of β-arrestin2 to human μ receptors in PathHunter CHO cells and ( B ) DAMGO as an inhibitor of forskolin (30 μM) stimulated cAMP accumulation in the same cell line transiently expressing the pGloSensor-22F protein following 16 h exposure to 1 μM PP2, PP3, eCF506 or an equal volume of DMSO. (A) Data are expressed as a percentage of maximum luminescence (% Max RLU) produced by DAMGO in DMSO exposed cells present in duplicate on each 96-well plate. The insert demonstrates c-Src phosphorylation at Y416 (upper panel) and total c-Src (lower panel) expression assessed using western blot in each cell lysate following overnight exposure and confirms inhibition of c-Src phosphorylation. (B) Data are expressed as a percentage of luminescence in each well measured prior to the addition of agonist (% control). Data from individual replicates were plotted and fitted with logistics functions to derive efficacy (E MAX ) and potency (EC 50 /IC 50 ) parameters, presented in . Data are the mean ± SEM of 5 replicates (A) and 8 replicates (B).

    Article Snippet: DAMGO ([D-Ala2, N-MePhe4, Gly-ol]-enkephalin) and forskolin (HelloBio, UK), morphine sulfate salt pentahydrate (#M8777), fentanyl citrate (#F3886), oxycodone hydrochloride (#BP1068; all from Merck, UK), TRV130 (#MBS3601671; CliniSciences, UK), buprenorphine hydrochloride (#2808), β-FNA (#0926), PP2 (#1407), PP3 (#2794), caffeic acid pYEEIE (#1935; all from Tocris, UK), DAS-5-oCRBN (#HY-163144; Cambridge Biosciences, UK) were prepared as 10 mM (DAMGO, morphine, fentanyl, buprenorphine, TRV130, PP2, PP3, DAS-5-oCRBN, caffeic acid-pYEEIE and eCF506), 20 mM (oxycodone), 25 mM (forskolin) or 100 mM (β-FNA) stock solutions in DMSO (DAMGO, forskolin, buprenorphine, β-FNA, PP2, PP3, DAS-5-oCRBN, caffeic acid-pYEEIE and eCF506) or water (fentanyl, morphine, oxycodone).

    Techniques: Concentration Assay, Expressing, Produced, Phospho-proteomics, Western Blot, Inhibition, Control

    Journal: bioRxiv

    Article Title: The c-Src inhibitor eCF506 diminishes opioid tolerance creating bias against β-arrestin2 recruitment

    doi: 10.1101/2025.07.01.662507

    Figure Lengend Snippet:

    Article Snippet: DAMGO ([D-Ala2, N-MePhe4, Gly-ol]-enkephalin) and forskolin (HelloBio, UK), morphine sulfate salt pentahydrate (#M8777), fentanyl citrate (#F3886), oxycodone hydrochloride (#BP1068; all from Merck, UK), TRV130 (#MBS3601671; CliniSciences, UK), buprenorphine hydrochloride (#2808), β-FNA (#0926), PP2 (#1407), PP3 (#2794), caffeic acid pYEEIE (#1935; all from Tocris, UK), DAS-5-oCRBN (#HY-163144; Cambridge Biosciences, UK) were prepared as 10 mM (DAMGO, morphine, fentanyl, buprenorphine, TRV130, PP2, PP3, DAS-5-oCRBN, caffeic acid-pYEEIE and eCF506), 20 mM (oxycodone), 25 mM (forskolin) or 100 mM (β-FNA) stock solutions in DMSO (DAMGO, forskolin, buprenorphine, β-FNA, PP2, PP3, DAS-5-oCRBN, caffeic acid-pYEEIE and eCF506) or water (fentanyl, morphine, oxycodone).

    Techniques: Inhibition, Concentration Assay, cAMP Assay

    Concentration-response relationships of DAMGO to recruit β-arrestin2 to human μ receptors in PathHunter CHO cells transiently overexpressing ( A ) full-length (residues 1-536; WT), ( B ) C-terminally truncated (residues 1-249) or ( C ) N-terminally truncated and catalytically inactive (residues 250-536(K298M)) human c-Src following 16-h exposure to PP2, PP3, eCF506 (300 nM) or an equal volume of DMSO. Data are expressed as a percentage of maximum luminescence (% Max RLU) produced by DAMGO in DMSO exposed cells present in duplicate on each plate i.e., cells overexpressing (A) WT, (B) Src 1-249 or (C) Src 250-536(K298M) are each expressed relative to the maximum β-arrestin2 recruitment of each construct caused by DAMGO. Data from individual replicates were plotted and fitted with logistics functions to derive efficacy (E MAX ) and potency (EC 50 ) parameters, presented in Supplementary Table 3. Data are the mean ± SEM of 5-6 replicates.

    Journal: bioRxiv

    Article Title: The c-Src inhibitor eCF506 diminishes opioid tolerance creating bias against β-arrestin2 recruitment

    doi: 10.1101/2025.07.01.662507

    Figure Lengend Snippet: Concentration-response relationships of DAMGO to recruit β-arrestin2 to human μ receptors in PathHunter CHO cells transiently overexpressing ( A ) full-length (residues 1-536; WT), ( B ) C-terminally truncated (residues 1-249) or ( C ) N-terminally truncated and catalytically inactive (residues 250-536(K298M)) human c-Src following 16-h exposure to PP2, PP3, eCF506 (300 nM) or an equal volume of DMSO. Data are expressed as a percentage of maximum luminescence (% Max RLU) produced by DAMGO in DMSO exposed cells present in duplicate on each plate i.e., cells overexpressing (A) WT, (B) Src 1-249 or (C) Src 250-536(K298M) are each expressed relative to the maximum β-arrestin2 recruitment of each construct caused by DAMGO. Data from individual replicates were plotted and fitted with logistics functions to derive efficacy (E MAX ) and potency (EC 50 ) parameters, presented in Supplementary Table 3. Data are the mean ± SEM of 5-6 replicates.

    Article Snippet: DAMGO ([D-Ala2, N-MePhe4, Gly-ol]-enkephalin) and forskolin (HelloBio, UK), morphine sulfate salt pentahydrate (#M8777), fentanyl citrate (#F3886), oxycodone hydrochloride (#BP1068; all from Merck, UK), TRV130 (#MBS3601671; CliniSciences, UK), buprenorphine hydrochloride (#2808), β-FNA (#0926), PP2 (#1407), PP3 (#2794), caffeic acid pYEEIE (#1935; all from Tocris, UK), DAS-5-oCRBN (#HY-163144; Cambridge Biosciences, UK) were prepared as 10 mM (DAMGO, morphine, fentanyl, buprenorphine, TRV130, PP2, PP3, DAS-5-oCRBN, caffeic acid-pYEEIE and eCF506), 20 mM (oxycodone), 25 mM (forskolin) or 100 mM (β-FNA) stock solutions in DMSO (DAMGO, forskolin, buprenorphine, β-FNA, PP2, PP3, DAS-5-oCRBN, caffeic acid-pYEEIE and eCF506) or water (fentanyl, morphine, oxycodone).

    Techniques: Concentration Assay, Produced, Construct

    (A) The presence of either gain-of-function or loss-of-function mutations in cancer driver genes can lead to cancer (left) or rare Mendelian disorders (right) in different contexts. Most cancers result from somatic mutations that accumulate in a tissue-specific manner, whereas germline mutations are present in all cells of the body and cause a type of rare Mendelian disorder (e.g., neurodevelopmental disorder). (B) The HRAS Q61K mutation is an example of a known cancer mutation that drives different types of cancers that also causes Costello syndrome, a developmental disorder, when observed as a germline variant. (C) Workflow for extracting cancer mutations from Cancer Hotspots. Recurrent cancer mutations were filtered to 2,447 missense mutations. See main text for details. REVEL scores thresholds correspond to supporting evidence for pathogenicity (PP3) and for benign-ness (BP4). Created with Lucidchart. Created with BioRender.

    Journal: PLOS Genetics

    Article Title: Leveraging cancer mutation data to inform the pathogenicity classification of germline missense variants

    doi: 10.1371/journal.pgen.1011540

    Figure Lengend Snippet: (A) The presence of either gain-of-function or loss-of-function mutations in cancer driver genes can lead to cancer (left) or rare Mendelian disorders (right) in different contexts. Most cancers result from somatic mutations that accumulate in a tissue-specific manner, whereas germline mutations are present in all cells of the body and cause a type of rare Mendelian disorder (e.g., neurodevelopmental disorder). (B) The HRAS Q61K mutation is an example of a known cancer mutation that drives different types of cancers that also causes Costello syndrome, a developmental disorder, when observed as a germline variant. (C) Workflow for extracting cancer mutations from Cancer Hotspots. Recurrent cancer mutations were filtered to 2,447 missense mutations. See main text for details. REVEL scores thresholds correspond to supporting evidence for pathogenicity (PP3) and for benign-ness (BP4). Created with Lucidchart. Created with BioRender.

    Article Snippet: We grouped these CH mutations by REVEL scores using the ClinGen-proposed PP3/BP4 score thresholds ( ) [ ].

    Techniques: Mutagenesis, Variant Assay